Drawn from an invited session at the American College of Rheumatology annual meeting, these publications have been judged the best clinical reports in rheumatology from the past year.
Among the revelations about gout treatment at this year’s meeting: Confusion among physicians about the definition of “control,” misunderstandings among gout patients about their own disease, and new drug options.
(AUDIO) A new paradigm in pain research provides simple ways to identify patients with disorders like arthritis or lupus who won't respond to standard treatments. Pain expert Daniel Clauw MD gives the details in this podcast.
Reports about lupus from the American College of Rheumatology meeting include news about biomarkers for non-atherosclerotic comorbidities, good results from epratuzumab and hydroxycloroquine, and good news about lymphoma risk.
A closer look at racial disparities in treatments for rheumatoid arthritis and osteoarthritis show nuanced explanations for why African Americans are less willing to undergo drug therapy and surgery. More careful and clearer communication may go a long way toward closing the gap.
Among major reports about Sjögren’s syndrome at the American College of Rheumatology meeting: An encouraging phase 2 trial for belimumab, two studies on severe manifestations, and a new screening test.
The reasons for the association aren't yet clear, but experts are warning that you should consider a fracture a red flag for cardiovascular risk in a patient with rheumatoid arthritis. Fractures also are associated with an increased mortality risk in general among RA patients.
New studies explore the neurology and psychology of pain in FM, patient knowledge, and evidence-based practice. The 2012 Canadian Fibromyalgia Guidelines recommend care by primary practitioners, not specialists.
A monoclonal antibody to TNF was effective for axial spondyloarthritis in a phase III trial, serum VEGF strongly predicted syndesmophyte formation, and a large database gave new insights on fracture risk.
(VIDEO) With rising attention to anti-citrullinated protein antibodies (ACPA) in RA classification, what is the current significance of rheumatoid factor? Rheumatologist Josef Smolen tells how he and others at the Medical University of Vienna addressed the question.